← Browse by Condition
Medical Condition
metastatic castration resistant prostate cancer mcrpc
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 3
NCT03903835 Phase 3
Recruiting
ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer
Enrollment
750 pts
Location
Belgium, Norway, Swe...
Sponsor
Karolinska Institutet
NCT06136650 Phase 3
Recruiting
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Enrollment
1,314 pts
Location
United States, Austr...
Sponsor
Merck Sharp & Dohme LLC